Therapeutic ISCOMATRIX™ adjuvant vaccine elicits effective anti-tumor immunity in the TRAMP-C1 mouse model of prostate cancer

Cancer vaccine development has proven challenging with the exception of some virally induced cancers for which prophylactic vaccines exist. Currently, there is only one FDA approved vaccine for the treatment of prostate cancer and as such prostate cancer continues to present a significant unmet medi...

Descripción completa

Detalles Bibliográficos
Autores principales: Barr, Adele M., Silva, Anabel, Prato, Sandro, Belz, Gabrielle T., Maraskovsky, Eugene, Baz Morelli, Adriana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7223769/
https://www.ncbi.nlm.nih.gov/pubmed/32388678
http://dx.doi.org/10.1007/s00262-020-02597-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7223769/
https://www.ncbi.nlm.nih.gov/pubmed/32388678
http://dx.doi.org/10.1007/s00262-020-02597-6

Ejemplares similares